Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
DAAs show good cure rates and liver function improvement for transplant recipients with recurrent HCV

Several presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston focused on treating hepatitis C recurrence in liver transplant

Published
8 hours ago
By
Liz Highleyman
FDA declines to approve Bristol-Myers hepatitis drug

Bristol-Myers said the FDA has asked it for data involving use of daclatasvir with other drugs, and that the company is in discussions with the agency about the scope of the required information.

Published
8 hours ago
From
Reuters
AbbVie 3D regimen cures recurrent HCV in most liver transplant recipients without cirrhosis

AbbVie's 3D regimen (newly named Viekirax + Exviera) demonstrated a sustained virological response rate of 97% for people with HCV genotype 1 recurrence after liver transplantation who had not

Published
8 hours ago
By
Liz Highleyman
"Promising" results in Oxford trials of Hepatitis C vaccine

A new vaccine developed by researchers at the University of Oxford has generated a strong immune response against the Hepatitis C virus in human volunteers. The vaccine is the first Hepatitis C inoculation to reach this stage of clinical trials, and the results have been promising. The 15 healthy human volunteers who took part in the phase 1 safety trial all responded positively.The study found that after the second, booster inoculation, all 15 volunteers had large, broad and sustained T cells responses.

Published
26 November 2014
From
Cherwell
Tenofovir continues to suppress hepatitis B virus for eight years

Most people with chronic hepatitis B who are treated with tenofovir for eight years continued to maintain viral suppression, researchers reported at the American Association for the Study

Published
25 November 2014
By
Liz Highleyman
Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C

An all-oral combination of daclatasvir (Daklinza) plus sofosbuvir (Sovaldi), taken for 12 weeks, produced sustained virological response rates of 90% for previously untreated patients and 86% for

Published
25 November 2014
By
Liz Highleyman
Deaths of Japanese patients prompt label change for simeprevir

The maker of Sovriad (simeprevir) has revised its package insert labeling on the order of Japanese health officials following the deaths of three people who took the hepatitis C drug.

Published
24 November 2014
From
HCP Live
CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe

Major regulatory milestone achieved toward approval in the European Union; final decision from the European Commission expected in the first quarter of 2015.

Published
21 November 2014
From
AbbVie press release
Ooh La La: France Negotiates a Steep Discount for Sovaldi From Gilead

The fixed price reduced the cost by about 27%, and so a 12-week regimen will now be priced at $51,400, instead of $71,100. This makes this the “lowest price in Europe,” according to the Economic Committee for Health Products. There is also stipulation that rebates will be made in the event of “treatment failure,” according to a statement from the agency.

Published
21 November 2014
From
Wall Street Journal
AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection

AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both produced good sustained virological response

Published
21 November 2014
By
Liz Highleyman
← First12345...149Next →

Filter by country